Unfavorably altered lipid profile in women with primary ovarian insufficiency.
Premature ovarian insufficiency (POI) is defined as the cessation of ovarian function before the age of 40 along with elevated levels of follicle-stimulating hormone (FSH)>25 IU/L1. POI is diagnosed among 1-2% of women worldwide and may be caused by chromosomal and genetic defects, autoimmune processes, chemotherapy, radiation, infections and surgery, however, majority of cases remain unidentified2. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 15, 2024 Category: Lipidology Authors: Pir óg Magdalena, Kacalska-Janssen Olga, Pulka Anna, Jach Robert Tags: Original Research Source Type: research
Remnant cholesterol is associated with the progression and regression of metabolic dysfunction-associated steatotic liver disease in Chinese adults
The prevalence of nonalcoholic fatty liver disease (NAFLD) has progressively increased over recent decades with increased rates of obesity and the rapid growth of the ageing population, affecting approximately 29% of the Chinese population (1). In addition to intrahepatic diseases such as liver cirrhosis and hepatocellular carcinoma, NAFLD has been demonstrated to increase the risks of multiple extrahepatic complications, including type 2 diabetes (T2DM), chronic kidney disease, cardiovascular disease (CVD), and even extrahepatic tumours (2,3). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 10, 2024 Category: Lipidology Authors: Wen Guo, Jing Lu, Xiaona Li, Xin Zhao, Nianzhen Xu, Qingqing Diao, Jue Jia, Qun Zhang Tags: Original Research Source Type: research
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES
Women are often underrepresented in clinical trials, leading to uncertainty in subgroup analyses by sex and lower quality data to guide evidence-based therapy.1,2 While many individual trials are inconclusive, patient-level meta-analyses show that women with established cardiovascular disease benefit from statin therapy to the same degree as men.3 However, sex-specific data for non-statin lipid-lowering therapies are sparse.2 A recent statement by the European Society of Atherosclerosis highlighted differences in lipoprotein concentrations through the life course in women versus men, as well as sex differences in the relat...
Source: Journal of Clinical Lipidology - April 9, 2024 Category: Lipidology Authors: Vera A. Bittner, Gregory G. Schwartz, Deepak L. Bhatt, Terrance Chua, H. Asita De Silva, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Jennifer McGinniss, Robert Pordy, Genevieve Garon, Michel Scemama, Harvey D. White, Ph. Gabriel Tags: Original Research Source Type: research
Long-term Cardiovascular Outcomes in a Population-Based Multicentric Cohort of Northern Portugal: Validation of the ESC/EAS Prognostic Risk Classification
The rising prevalence of cardiovascular (CV) risk factors in Portugal translates into more than 35 000 annual deaths due to CV diseases, representing 30% of the total mortality in 2019 1,2. Moreover, CV risk factors such as dyslipidemia, obesity, hypertension, type 2 diabetes, smoking, coronary artery disease, history of stroke, myocardial infarction, among others can significantly increase the risk of subsequent CV events 3. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 4, 2024 Category: Lipidology Authors: Cristina Gavina, Daniel Seabra Carvalho, Marta Afonso-Silva, Daniela Brand ão Abreu, Mariana Canelas-Pais, Tiago Taveira-Gomes, Francisco Araújo Tags: Original Research Source Type: research
Sex, Racial, Ethnic, and Geographical Disparities in Major Adverse Cardiovascular Outcome of Glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A Meta-analysis of Placebo-Controlled Randomized Controlled Trials
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a first-line drug in treating type 2 diabetes mellitus (T2DM).1 GLP-1RAs have also been found to significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM, as demonstrated by multiple large cardiovascular outcome trials (CVOTs).2, 3 The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial (2016), which aimed to determine the cardiovascular (CV) effects of liraglutide marked a turning point and was the first to show a reduction in major adverse cardiovascular events (...
Source: Journal of Clinical Lipidology - April 4, 2024 Category: Lipidology Authors: Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw Tags: Original Research Source Type: research
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
The lipoprotein(a) [Lp(a)] field is rapidly evolving on many fronts, warranting this focused update to the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice.1 Recent evidence has influenced our understanding of whom should have Lp(a) levels measured, how to interpret Lp(a) levels for use in risk assessment, and clinical management of patients with elevated Lp(a). The NLA now recommends: (1) measurement of Lp(a) levels at least once in every adult; (2) classification of individuals with Lp(a) levels (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - April 1, 2024 Category: Lipidology Authors: Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, Dave L. Dixon, Keith C. Ferdinand, Samuel S. Gidding, Edward A. Gill, Terry A. Jacobson, Erin D. Michos, Maya S. Safarova, Daniel E. Soffer, Pam R. Taub, Michael J. Wilkinson, Don P. Wilson, Christie M Source Type: research
Application of implementation science for improving the utilization of an international clinical practice guidance on familial hypercholesterolemia
Implementation science evolved into a field of research to accelerate the translation of evidence into practice (1,2). While major advances have been made to reduce the time for evidence to be translated into practice, there has been less progress on improving the uptake of clinical practice guidelines. Several guidelines (3-12) and position statements (13-15) in cardiovascular disease have recommended that implementation science approaches be used to address gaps in care. More recently, models have been developed for guideline contributors to embed implementation recommendations into the guideline development and translat...
Source: Journal of Clinical Lipidology - April 1, 2024 Category: Lipidology Authors: Laney K. Jones, Samuel S. Gidding, Raul D. Santos, Peter Libby, Gerald F. Watts, Mitchell N. Sarkies Tags: Original Research Source Type: research
Lipid-lowering optimisation for secondary prevention vascular and diabetic foot patients in a pharmacist-led clinic
Cardiovascular disease (CVD) is the leading cause of death accounting for a quarter of all deaths in the UK and more than 100,000 hospital admissions1. Stroke causes 38,000 deaths and 100,000 admissions in the UK annually2. Associated healthcare costs are estimated to be £9 billion every year with an overall CVD burden of approximately £19 billion annually3. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 29, 2024 Category: Lipidology Authors: Matthew Hart Mpharm, Jon Rees, Julia L Newton, Gerard Stansby, Kate Mackay, Ahai Luvai Tags: Original Research Source Type: research
The role of genetically-influenced phospholipid transfer protein activity in lipoprotein metabolism and coronary artery disease
The phospholipid transfer protein (PLTP) facilitates the transfer of surface phospholipids between lipoprotein particles. For example, during the lipolytic conversion of triglyceride-rich lipoproteins (TRLs), PLTP transfers excess phospholipids to high-density lipoprotein (HDL), allowing TRL remnants to reduce in size (1-3). As such, PLTP plays an important role in the metabolism of both TRLs and HDL, and affects their particle size and composition. Evidence regarding the association of PLTP activity with coronary artery disease (CAD) is inconsistent. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 29, 2024 Category: Lipidology Authors: Linjun Ao, Raymond Noordam, Patrick C.N. Rensen, Diana van Heemst, Ko Willems van Dijk Tags: Original Research Source Type: research
Detecting Familial Hypercholesterolemia: An Observational Study Leveraging Mandatory Universal Pediatric Total Cholesterol Screening in Slovakia
Familial hypercholesterolemia (FH) is an autosomal-dominant inherited disorder that is often underdiagnosed and undertreated. FH is characterized by a lifelong exposure to high levels of low-density lipoprotein cholesterol (LDL-C), which causes early and accelerated atherogenesis. Patients with genetically defined FH have a risk of coronary heart disease that is>10-fold than that of the general population, and a 3-fold increased risk of cardiovascular disease at the same LDL-C level.1 The relative cardiovascular risk patients with FH is highest between the ages of 25 and 40 years. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 29, 2024 Category: Lipidology Authors: Katarina Raslova, Viera Donicova, Katarina Gonova, Alexander Klabnik, Lukas Tichy, Ian Bridges, Dagmar Buckova, Marie Zachlederova, Tomas Freiberger, Branislav Vohnout Tags: Original Research Source Type: research
Genetically and Clinically Confirmed Atypical Cerebrotendinous Xanthomatosis with Normal Cholestanol and Marked Elevations of Bile Acid Precursors and Bile Alcohols
Cerebrotendinous xanthomatosis (CTX, OMIM 213700) is a rare autosomal recessive disorder associated with deficiency of the CYP27A1 enzyme (sterol 27-hydroxylase), encoded by the CYP27A1 gene1, 2. The presentation of clinical features in CTX is complex, with heterogeneous symptoms, variable severity and evolution of complications, and diverse differences in progression of disease even within the same family1, 2. In a series of 43 cases in the United States, the mean age at diagnosis was 32 years3. In these patients, 53% experienced chronic diarrhea in childhood, 74% had cognitive impairment in childhood adolescence, 70% wer...
Source: Journal of Clinical Lipidology - March 15, 2024 Category: Lipidology Authors: Andrea E DeBarber, Ernst J. Schaefer, Jenny Do, Joseph W Ray, Austin Larson, Samantha Redder, Maya Fowler, P Barton Duell Tags: Original Research Source Type: research
Longitudinal analysis of clinical and laboratory biomarkers in a patient with Familial Lecithin: Cholesterol acyltransferase deficiency (FLD) and accelerated eGFR decline: a case study.
Familial LCAT Deficiency (FLD) is an ultra-rare autosomal recessive disorder caused by complete loss of function variants in the gene encoding for lecithin:cholesterol acyltransferase (LCAT).1FLD is characterized by very low HDL-Cholesterol (HDL-C) levels, often reduced LDL-Cholesterol (LDL-C) levels, elevated and variable triglycerides (TG), and the presence of abnormal lipoproteins such as lipoprotein X (LpX), which is believed to be nephrotoxic.1 Despite having significantly reduced HDL-C levels, FLD patients are not higher risk of atherosclerotic cardiovascular disease. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 13, 2024 Category: Lipidology Authors: Gregory Alfaro, Jay Pendyala, Michael Sulewski, Michael Miller, Cecilia Vitali, Marina Cuchel Tags: Case Study Source Type: research
Effect of Statin Use on Liver Enzymes and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with the prevalence of approximately 30%.1 The prevalence goes up among specific high-risk populations: 30-50% in patients with type 2 diabetes, and 80-90% in patients with obesity.2,3 (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 12, 2024 Category: Lipidology Authors: Anh Ho, Takako Kiener, Quynh-Nhu Nguyen, Quang A. Le Tags: Original Research Source Type: research
Overcoming the real and imagined barriers to cholesterol screening in pediatrics
The recent United States Preventive Services Task Force (USPSTF) recommendation statement declaring incomplete evidence for or against universal lipid screening in young people has highlighted both discordances with previously published multi-national and multi-society guidelines and evidence gaps related to lipid screening early in life.1 Conflicting recommendations add unnecessary challenges that delay incorporation of screening, identification, and treatment of young people with lipid disorders, particularly familial hypercholesterolemia (FH). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - March 5, 2024 Category: Lipidology Authors: Tyler J. Schubert, Samuel S. Gidding, Laney K. Jones Tags: Editorial Source Type: research
Malar rash and hand tremor in early symptoms of cerebrotendinous xanthomatosis and the effect of chenodeoxycholic acid on them
Cerebrotendinous xanthomatosis (CTX, OMIM #213700) is a rare, autosomal recessive, neurodegenerative lipid storage disease with multisystemic involvement.1 The incidence of CTX is estimated to be between 1/72000-1/150000, and prevalence is 3/100000-5/100000.2 CTX disease occurs due to mutations in the CYP27A1 gene on chromosome 2, which causes defects in synthesizing the sterol 27-hydroxylase enzyme that plays a role in mitochondrial cholesterol metabolism and bile acid synthesis.1,3 This enzyme deficiency causes a decrease in the production of cholic acid and chenodeoxycholic acid and an increase in the production of chol...
Source: Journal of Clinical Lipidology - February 28, 2024 Category: Lipidology Authors: Banu Kad ıoğlu Yılmaz, Halil Çelik Tags: Original Research Source Type: research
